Misplaced Pages

Oxipurinol

Names
Preferred IUPAC name 1H-pyrazolopyrimidine-4,6(2H,5H)-dione
Other names 2,5-Dihydro-1H-pyrazolopyrimidine-4,6-dione Alloxanthine
Identifiers
CAS Number	2465-59-0
3D model (JSmol)	Interactive image
Beilstein Reference	139956
ChEBI	CHEBI:28315
ChEMBL	ChEMBL859
ChemSpider	4483
ECHA InfoCard	100.017.792
EC Number	219-570-9
KEGG	C07599
MeSH	Oxypurinol
PubChem CID	4644
UNII	G97OZE5068
CompTox Dashboard (EPA)	DTXSID4035209
InChI InChI=1S/C5H4N4O2/c10-4-2-1-6-9-3(2)7-5(11)8-4/h1H,(H3,6,7,8,9,10,11)Key: HXNFUBHNUDHIGC-UHFFFAOYSA-N
SMILES O=C1NC(=O)C2=CNNC2=N1
Properties
Chemical formula	C5H4N4O2
Molar mass	152.11086
Appearance	white crystals
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). Infobox references

Oxipurinol (INN, or oxypurinol USAN) is an inhibitor of xanthine oxidase. It is an active metabolite of allopurinol and it is cleared renally. In cases of renal disease, this metabolite will accumulate to toxic levels. By inhibiting xanthine oxidase, it reduces uric acid production. High serum uric acid levels may result in gout, kidney stones, and other medical conditions.

References

1. Stocker, Sophie L; McLachlan, Andrew J; Savic, Radojka M; Kirkpatrick, Carl M; Graham, Garry G; Williams, Kenneth M; Day, Richard O (2012). "The pharmacokinetics of oxypurinol in people with gout". British Journal of Clinical Pharmacology. 74 (3): 477–489. doi:10.1111/j.1365-2125.2012.04207.x. PMC 3477349. PMID 22300439.
2. Elion, Gertrude B; Yü, Ts'ai-Fan; Gutman, Alexander B; Hitchings, George H (1968). "Renal clearance of oxipurinol, the chief metabolite of allopurinol". The American Journal of Medicine. 45 (1): 69–77. doi:10.1016/0002-9343(68)90008-9. PMID 5658870.

This article about a heterocyclic compound is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Pyrazolopyrimidines
• Xanthine oxidase inhibitors
• Human drug metabolites
• Heterocyclic compound stubs